Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 14 4 2024 12 30 Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications 737 744 10.34172/apb.43306 EN Daohong Chen https://orcid.org/0000-0003-4060-6050 EDITORIAL 10.34172/apb.43306 2024 06 20 2024 09 08 Purpose: It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective. Methods: Literature review and re-thinking. Results: This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond. Conclusion: Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.